切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (01) : 50 -52. doi: 10.3877/cma.j.issn.2095-3232.2015.01.014

所属专题： 文献；

基础研究

siRNA沉默HCCR-2基因抑制卵巢癌肝转移的实验研究
王晶1, 梁建明2, 刘安琪3, 陈文捷4, 何勉1,†()   
  1. 1. 510080　广州，中山大学附属第一医院妇产科
    2. 510080　广州，中山大学附属第一医院检验科
    3. 510630　广州，中山大学附属第三医院科研科
    4. 510630　广州，中山大学附属第三医院肝脏病实验室
  • 收稿日期:2014-10-19 出版日期:2015-02-10
  • 通信作者: 何勉
  • 基金资助:
    国家自然科学基金(81302550，81301331); 广东省自然科学基金(S2013010015552)

Inhibition of HCCR-2 gene expression by siRNA suppresses liver metastasis of ovarian cancer

Jing Wang1, Jianming Liang2, Anqi Liu3, Wenjie Chen4, Mian He1,†()   

  1. 1. Department of Obstetrics and Gynecology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
    2. Department of Laboratory, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
    3. Research Service office, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    4. Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2014-10-19 Published:2015-02-10
  • Corresponding author: Mian He
  • About author:
    Corresponding author: He Mian, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王晶, 梁建明, 刘安琪, 陈文捷, 何勉. siRNA沉默HCCR-2基因抑制卵巢癌肝转移的实验研究[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(01): 50-52.

Jing Wang, Jianming Liang, Anqi Liu, Wenjie Chen, Mian He. Inhibition of HCCR-2 gene expression by siRNA suppresses liver metastasis of ovarian cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(01): 50-52.

目的

探讨siRNA抑制人宫颈癌基因2（HCCR-2）表达对卵巢癌肝转移能力的影响。

方法

HCCR-2-siRNA慢病毒表达载体及空载体对照质粒感染人卵巢癌高转移细胞HO-8910PM，建立小干扰（SI）组和空白对照（NC）组。采用Western blot检测HCCR-2蛋白表达。采用Transwell法检测癌细胞侵袭能力，卵巢癌肝转移模型裸鼠观察癌细胞转移能力。两组实验数据比较采用t检验，率的比较采用χ2检验。

结果

SI组细胞HCCR-2蛋白的平均相对表达量为0.16±0.02，较NC组的0.86±0.05明显减少（t=-8.06，P<0.05）。SI组的穿膜细胞数为（58±3）个，较NC组的（262±19）个明显减少（t=-37.77，P<0.05）。SI组的肝转移癌发生率2/6，较NC组的6/6明显降低（P<0.05）；SI组成瘤数量为（1.3±0.2）个，较NC组的（9.4±0.8）个明显减少（t=-10.25，P<0.05）。

结论

siRNA沉默抑制HCCR-2基因表达可降低卵巢癌细胞的侵袭和肝转移能力。

关键词: 肿瘤，未知原发灶, 肝肿瘤, 卵巢肿瘤, 人宫颈癌基因2
Objective

To investigate the impact of human cervical cancer oncogene-2 (HCCR-2) inhibited by small interference RNA (siRNA) on the liver metastatic potential of ovarian cancer.

Methods

High metastatic ability human ovarian cancer cell line HO-8910PM was infected using HCCR-2-siRNA lentiviral expression vector and empty negative control vector to establish small interference (SI) group and negative control (NC) group. The expression of HCCR-2 protein in two groups was detected by Western blot assay. Transwell assay was used to define the cell invasion ability. Liver metastases model of ovarian cancer was established to detect the cell metastatic ability. The data between two groups were compared using t test, and the rates were compared using Chi-square test.

Results

The average relative expression of HCCR-2 protein in SI group (0.16±0.02) significantly decreased compared with that in NC group (0.86±0.05) (t=-8.06, P<0.05). The membrane permeating cell count in SI group (58±3) was significantly less than that in NC group (262±19) (t=-37.77, P<0.05). The incidence of liver metastases in SI group (2/6) was significantly lower than that in NC group (6/6) (P<0.05). The number of metastases in SI group (1.3 ± 0.2) was significantly less than that in NC group (9.4 ± 0.8) (t = -10.25, P<0.05).

Conclusion

Inhibition of HCCR-2 gene expression by siRNA can reduce the invasion and liver metastatic potential of ovarian cancer cells.

Key words: Neoplasms, unknown primary, Liver neoplasms, Ovarian neoplasms, Human cervical cancer oncogene-2
[1]
Jirun P, Zhang G, Ha SA, et al. HCCR-1 for detecting small hepatocellular carcinoma latent in a cirrhotic liver: a prospective cohort study[J]. Gut, 2012, 61(10):1514-1515.
[2]
Ha SA, Kim HK, Yoo JA, et al. HCCRBP-3 induces tumorigenesis through direct interaction with HCCR-1 in human cancers[J]. Mol Carcinog, 2014, 53(1):30-37.
[3]
Lalmahomed ZS, Ayez N, van der Pool AE, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome?[J]. World J Surg, 2011, 35(3):656-661.
[4]
Kazaryan AM, Marangos IP, Rosok BI, et al. Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome[J]. Ann Surg, 2010, 252(6):1005-1012.
[5]
Kim KH, Yoon YS, Yu CS, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases[J]. J Korean Surg Soc, 2011, 81(1):25-34.
[6]
Lermite E, Marzano E, Chereau E, et al. Surgical resection of liver metastases from breast cancer[J]. Surg Oncol, 2010, 19(4):e79-84.
[7]
Snoeren N, van Hooff SR, Adam R, et al. Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases[J]. PLoS One, 2012, 7(11):e49442.
[8]
Li H, Yang W, Chen PW, et al. Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases[J]. Invest Ophthalmol Vis Sci, 2009, 50(12):5522-5528.
[9]
Qiao SS, Cui ZQ, Gong L, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma[J]. Hepatogastroenterology, 2011, 58(110/111):1718-1724.
[10]
Ha SA, Kim HK, Yoo J, et al. Transdifferentiation-inducing HCCR-1 oncogene[J]. BMC Cell Biol, 2010(11):49.
[11]
Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study[J]. Dis Markers, 2012, 32(4):265-271.
[12]
Xu Z, Zhang Y, Jiang J, et al. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells[J]. BMC Cancer, 2010, 10(1):161.
[13]
Ha SA, Lee YS, Shin SM, et al. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status[J]. BMC Cancer, 2009, 9(1):51.
[1] 卢菊, 赵胜, 范建华, 高艳多. 探讨IOTA、GI-RADS及O-RADS在附件肿瘤良恶性鉴别诊断中的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(05): 484-490.
[2] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[5] 刘庭秀, 刘新敏, 刘莹, 隋娟, 武宇, 赵瑜敬, 毕红, 孙雪梅, 范秀华. 腹壁整形术后腹腔镜新脐入路治疗卵巢肿物的安全性探讨[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(03): 189-192.
[6] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[7] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[8] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[9] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[10] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[11] 欧阳佳裕, 李刚, 贺露瑶, 罗娜. 双层探测器光谱CT在早期原发性肝癌中的诊断价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 557-561.
[12] 王凯飞, 牟怡平, 李晓辉, 王瑞涛, 侯惠莲, 张月浪. 原发性肝平滑肌肉瘤临床病理特征及疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 357-362.
[13] 陈志坚, 俞建达, 池小斌, 吕立志, 陈永标. 三维可视化技术在腹腔镜肝巨大肿瘤切除中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 302-307.
[14] 黄俊豪, 陈宗杰, 胡添松. 血小板相关参数对肝内胆管细胞癌根治性切除患者预后预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 308-312.
[15] 马欢欢, 马晨辉, 邓小博, 王博方, 何普毅, 王云鹏, 许博, 俞荣, 王娜, 陈昊. 肝癌实体瘤治疗疗效评价系统的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 377-383.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号